Recalled Medicines & supplements – Current GIS Alerts 2026
Found 713 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Dolofest
The product does not meet the specified quality requirement due to an out-of-specification (OOS) result for the sachet tightness parameter. Potential effects: reduced medicine quality, possible decrease in efficacy or risk of impaired product stability.
Withania Somnifera Ashwagandha cut root
An exceedance of the maximum permitted level of the pesticide chlorpyrifos was found in the Ashwagandha product, which according to risk assessment may potentially pose a health risk to consumers. Potencjalne skutki: poisoning, neurotoxic effects, other adverse health effects.
Withania Somnifera Ashwagandha – capsules
An exceedance of the maximum permitted level of the pesticide chlorpyrifos (0.09 mg/kg) was found in Ashwagandha capsules, which may potentially pose a health risk to consumers according to NIPH-NIH risk assessments. Potencjalne skutki: poisoning, neurotoxic effects, other adverse health effects.
Mother’s Protect Ahwagandha live herbs food supplement, 50 ml
Residues of the pesticide chlorpyrifos were detected in the product, which may expose consumers to the harmful effects of this substance. Potential effects: poisoning, neurotoxic effects, other acute or chronic symptoms.
Gastrografin
Tests showed the presence of N-nitroso-meglumine contamination exceeding the acceptable daily intake and the temporary LTL limit for contrast agents. N-nitroso-meglumine is regarded as a potentially carcinogenic impurity. Potential effects: increased risk of carcinogenic effects and other complications related to long-term exposure.
Gastrografin
Based on tests of a representative number of batches of the medicinal product manufactured from December 2020 to April 2024, the presence of N-nitroso-meglumine contamination was confirmed, with a content exceeding the acceptable intake (AI) limit of 100 ng/day. N-nitroso-meglumine is considered a potential carcinogenic impurity. Potential effects: increased carcinogenic risk and harm to patient health.
Vendal retard
The medicinal product does not meet quality requirements: a single unknown impurity (related substances) was detected at a level exceeding the permitted limits in the product specification. Potential effects: possible alteration of drug effect or increased risk of adverse reactions.
Oxaliplatin Eugia
Testing by the National Medicines Institute showed an out-of-specification result for appearance - contamination with particles visible to the naked eye, meaning the product intended for intravenous infusion does not meet quality requirements. Potencjalne skutki: thromboembolic complications, vascular damage, inflammatory reactions, lack of treatment safety.
Inuprin Forte
In many packs, an insoluble sediment of sucrose crystals was found at the bottom of the bottles, constituting a quality defect and potentially affecting the effectiveness of preservatives and antimicrobial protection during storage after opening. Potential effects: impaired medicine quality and possible reduction of effectiveness and safety.
Ahwagandha live herbs dietary supplement, 50 ml
The product was found to exceed the maximum permitted level of the pesticide chlorpyrifos. Due to its toxicological properties, any level exceeding the MRL may potentially pose a risk to consumer health. Potencjalne skutki: possible toxic effects, health disturbances, chemical poisoning.
Lorazepam TZF
The product does not meet quality requirements due to a failed test for the parameter "volume of liquid obtained from a single-dose container"; for some units the volume was below the lower limit of the quality specification. Potential effects: insufficient dosing of the medicine and lack of the intended therapeutic effect.
Lorazepam TZF
The product does not meet quality requirements due to an out-of-specification result for the parameter "volume of liquid obtained from the single-dose container" - in some ampoules the volume was below the lower limit in the registered specification. Potencjalne skutki: insufficient dosing, reduced treatment efficacy, possible disease complications.
Jaxteran
The National Medicines Institute found that the product does not meet quality requirements: in 6 of 68 capsules there were 9 mini-tablets instead of the required 10, meaning a reduced dose of active substance in some capsules. Potential effects: reduced treatment efficacy, risk of incomplete therapeutic response.
Omnipaque
The manufacturer detected metal particles originating from the mold used for 100 ml polypropylene bottles, causing contamination of the solution for injection and adherent/deposited solid particles in the bottles. The defect was assessed as posing a high risk to patients' health and life. Potential effects: parenteral complications, particle embolism, severe reactions, life-threatening events.
Visipaque
Presence of foreign bodies was detected - metal particles detached from the mold used to produce 100 ml polypropylene bottles, contaminating the solution for injection and creating a high risk to patients' health and life. Potential effects: vascular embolism, severe thromboembolic complications, inflammatory reactions, life-threatening events.
Curosurf
The Italian Medicines Agency (AIFA) indicated an increased risk of microbiological contamination in batches of Curosurf after analysis of environmental microbiological monitoring data. A risk to patients' health or life cannot be excluded. Potential effects: infection, serious complications, lack of treatment efficacy.
Curosurf
An increased risk of microbiological contamination was identified for batches manufactured in 2024-2025, which may realistically endanger the quality of the medicinal product and the health or life of patients. Potential effects: infections, serious complications, lack of treatment efficacy.
Sunitinib MSN
Leakage of capsules was found, with yellow powder present in intact blister pockets and a risk of environmental exposure to the cytotoxic substance spilling from the damaged capsule. Potential effects: poisoning, irritation and other toxic effects, lack of dose control of the medicine.
Tullex
During long-term stability testing of Tullex 20 mg, an out-of-specification result was observed: microbial growth was detected in the sterility test, indicating a justified suspicion of microbiological contamination of an injectable medicinal product. Potential effects: infection, severe local or systemic complications, sepsis.
Medoxa
The National Medicines Institute reported an out-of-specification result for the parameter "appearance": tablets were non-homogeneous and some had an additional score line; during packaging, thicker and broken tablets were also found. Potential effects: improper dosing of the drug, reduced efficacy or increased adverse reactions.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.